Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21812523 | 0.86 | GAA (0.56) | ALDH1A1GAAHTTAPOBEC3GKDM4E | |
| SCHEMBL21812521 | 0.86 | GAA (0.56) | ALDH1A1GAAHTTAPOBEC3GKDM4E | |
| SCHEMBL9936974 | 0.83 | GAA (0.45) | ALDH1A1GAAHTTAPOBEC3GKDM4E | |
| SCHEMBL9936971 | 0.83 | GAA (0.45) | ALDH1A1GAAHTTAPOBEC3GKDM4E | |
| SCHEMBL9936595 | 0.81 | GAA (0.61) | ALDH1A1GAAHTTAPOBEC3GKDM4E | |
| SCHEMBL9936605 | 0.81 | GAA (0.53) | ALDH1A1GAAHTTAPOBEC3GKDM4E | |
| SCHEMBL9936906 | 0.80 | GAA (0.51) | ALDH1A1GAAHTTAPOBEC3GKDM4E | |
| SCHEMBL13485775 | 0.79 | GAA (0.63) | ALDH1A1GAAHTTAPOBEC3GKDM4E | |
| SCHEMBL9936614 | 0.77 | GAA (0.56) | ALDH1A1GAAHTTAPOBEC3GKDM4E | |
| SCHEMBL12376697 | 0.75 | KDM4E (0.49) | KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651897-B1 | PROCESS FOR DEPIGMENTING KERATIN MATERIALS USING THIOPYRIDINONE COMPOUNDS | OREAL (FR) | 2020-04-01 | — | — | EP | claimed |
| EP-2651897-A1 | PROCESS FOR DEPIGMENTING KERATIN MATERIALS USING THIOPYRIDINONE COMPOUNDS | L'Oréal (FR) | 2013-10-23 | — | — | EP | claimed |
| WO-2012080075-A1 | PROCESS FOR DEPIGMENTING KERATIN MATERIALS USING THIOPYRIDINONE COMPOUNDS | L'OREAL (FR) | 2012-06-21 | — | — | WO | claimed |
| US-20240293301-A1 | PROCESS FOR DEPIGMENTING KERATIN MATERIALS USING THIOPYRIDINONE COMPOUNDS | L'OREAL (FR) | 2024-09-05 | — | — | US | disclosed |
| US-20210401709-A1 | PROCESS FOR DEPIGMENTING KERATIN MATERIALS USING THIOPYRIDINONE COMPOUNDS | L'ORÉAL (FR) | 2021-12-30 | — | — | US | disclosed |
| US-11052028-B2 | Process for depigmenting keratin materials using thiopyridinone compounds | L'OREAL (FR) | 2021-07-06 | — | — | US | disclosed |
| EP-2651897-B1 | PROCESS FOR DEPIGMENTING KERATIN MATERIALS USING THIOPYRIDINONE COMPOUNDS | OREAL (FR) | 2020-04-01 | — | — | EP | disclosed |
| US-20160045420-A1 | PROCESS FOR DEPIGMENTING KERATIN MATERIALS USING THIOPYRIDINONE COMPOUNDS | L'OREAL (FR) | 2016-02-18 | — | — | US | disclosed |
| US-20160045420-A1 | PROCESS FOR DEPIGMENTING KERATIN MATERIALS USING THIOPYRIDINONE COMPOUNDS | L'OREAL (FR) | 2016-02-18 | — | — | US | disclosed |
| US-9138392-B2 | Process for depigmenting keratin materials using thiopyridinone compounds | L'OREAL (FR) | 2015-09-22 | — | — | US | disclosed |
| US-9138392-B2 | Process for depigmenting keratin materials using thiopyridinone compounds | L'OREAL (FR) | 2015-09-22 | — | — | US | disclosed |
| WO-2012080075-A1 | PROCESS FOR DEPIGMENTING KERATIN MATERIALS USING THIOPYRIDINONE COMPOUNDS | L'OREAL (FR) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160045420-A1 | PROCESS FOR DEPIGMENTING KERATIN MATERIALS USING THIOPYRIDINONE COMPOUNDS | CBR3, RTN3, HRH4 | ALDH1A1 1647/4885GAA 4768/4885HTT 1773/4885 |
| US-20240293301-A1 | PROCESS FOR DEPIGMENTING KERATIN MATERIALS USING THIOPYRIDINONE COMPOUNDS | CBR3, RTN3, HRH4 | ALDH1A1 1679/4885GAA 4771/4885HTT 1842/4885 |
| US-20210401709-A1 | PROCESS FOR DEPIGMENTING KERATIN MATERIALS USING THIOPYRIDINONE COMPOUNDS | CBR3, HRH4, RTN3 | ALDH1A1 1705/4885GAA 4751/4885HTT 1473/4885 |
| US-11052028-B2 | Process for depigmenting keratin materials using thiopyridinone compounds | KRT18, PKN1, PTMA | ALDH1A1 1269/4885GAA 2542/4885HTT 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.